03 December
2024
Graft Polymer (UK) Plc
(the "Company")
Proposed change of name to
Solvonis Therapeutics Plc
Continuing progress with the
Awakn collaboration
Proposed change of name
Graft Polymer (UK) Plc
(LON:GPL) announces its intention to change
its name to Solvonis Therapeutics Plc, subject to approval of its
shareholders at a general meeting of the Company (the "GM"), to be
held at Eccleston Yards, 25 EP, Victoria, London, SW1W 9NF on
6 January, 2025 at 1:00pm GMT. This resolution will be proposed as a special
resolution.
The proposed name, "Solvonis
Therapeutics Plc" aligns more closely with the Company's strategic
focus on developing intellectual property and co-developing
therapeutics to address mental health and substance use
disorders.
"Solvonis" reflect the Company's
mission to improve outcomes for individuals and families affected
by mental health and substance use disorders. The Company's initial
focus is on trauma-related mental health disorders, such as
post-traumatic stress disorder ("PTSD"). This mission will continue to be executed through the
Company's previously stated plan of joint ventures, strategic
partnerships, and mergers and acquisitions.
The proposed name change will be
presented as a special resolution at the GM. Details of the GM,
including the time and venue, will be included in the Notice of the
General Meeting, which has been dispatched to shareholders today
and made available on the Company's website.
The Board of Directors unanimously
supports the proposed name change, believing it aligns with the
Company's strategic objectives and serves the best interests of the
Company and its shareholders. The Board recommends that
shareholders vote in favour of the resolution to be proposed at the
GM.
Continuing Progress with the Awakn
Collaboration
The Company is pleased to report
continued progress in its Aminoindane New Chemical Entity (NCE)
collaboration with Awakn, originally announced on 18 July 2024.
This collaboration represents an important step in the Company's
efforts to advance innovative therapeutics for mental health.
Results from the initial studies, conducted in partnership with
Eurofins Discovery and the University of Nottingham, are expected
to be reported imminently, marking a key development in the
programme.
Charnwood Discovery, Awakn's
selected synthesis partner (announced on 28 August 2024), was
acquired by Concept Life Sciences on 5 November 2024. Awakn has
confirmed that its collaboration will continue with Concept Life
Sciences, ensuring a smooth transition for any further synthesis
activities required to advance the Aminoindane NCE programme. These
developments highlight the continued momentum and focus on
delivering progress within this promising area of therapeutic
research.
Enquiries:
Graft Polymer (UK) Plc
Anthony Tennyson, CEO and Executive Director.
anthonytennyson@graftpolymer.co.uk
Allenby Capital (Broker) +44 (0) 20
3328 5656
Nick Naylor / Liz Kirchner
(Corporate Finance) | Guy McDougall (Sales)
About Graft Polymer (UK) Plc
Graft Polymer (UK) Plc is an
innovative biotechnology company focused on developing intellectual property relating to the treatment of
mental health and substance use disorders, and the co-development
of therapeutics for mental health disorders. Our mission is to improve outcomes for individuals
suffering from these conditions, with an initial focus on
trauma-related mental health disorders, such as PTSD, which affects
approximately 13 million adults in the U.S. and 20 million in US,
UK, and key EU markets.
For more information, please
visit www.graftpolymer.co.uk.